Subcellular Targeting of Theranostic Radionuclides

Area of Science:

• Nuclear medicine
• Radiochemistry
• Oncology

Background:

• Theranostic radionuclides are increasingly used for cancer treatment and imaging.
• Targeted radionuclide therapy (TRT) often uses beta-emitting radionuclides due to their longer particle range.
• Alpha- and Auger electron-emitting radionuclides offer higher ionization density for potentially reduced toxicity.

Purpose of the Study:

• To review the current research on subcellular targeting of radionuclide theranostics.
• To discuss methods for imaging and quantifying radionuclide localization at the nanoscale.
• To highlight the need for improved techniques to assess subcellular distribution.

Main Methods:

• Review of current literature on theranostic radionuclide research.
• Discussion of imaging and quantification techniques for nanoscale radionuclide distribution.
• Analysis of the role of subcellular targeting in TRT.

Main Results:

• Beta-emitting radionuclides dominate TRT due to particle range, but alpha and Auger electron emitters offer potential advantages.
• Subcellular targets like cell membranes and mitochondria are emerging as critical in TRT.
• Accurate detection of radionuclide subcellular distribution is crucial for developing precise TRT agents.

Conclusions:

• Developing TRT agents requires parallel advancements in quantitative assays for nanoscale radionuclide distribution.
• Improved imaging and quantification methods are essential for evaluating subcellular localization of theranostic radionuclides.
• Understanding subcellular distribution is key to optimizing targeted radionuclide therapy for cancer.